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Summary
Targeting the microtubule system represents an attrac-
tive strategy for the development of anticancer agents.
In this study, we report a class of combretastatin A-4
(CA-4) analogs derivatized with a boronic acid moiety
replacing the hydroxyl group on the C-ring of CA-4.
Docking studies of the X-ray structures of our aryl-
boronic analogs onto an X-ray structure of the ,-
tubulin heterodimer suggested that cis-6 was a potent
inhibitor of the colchicine binding. The model indi-
cated that there would be strong hydrogen bonding
between the boronic acid moiety and Thr-179 and Val-
181 of -tubulin. We demonstrate that the cis-6 bo-
ronic acid bioisostere of CA-4: (1) inhibits tubulin as-
sembly, (2) competitively displaces colchicine, and (3)
is a low-nanomolar inhibitor of human cancer cell
lines. We present this isostere as a class of potent
analogs of CA-4.
Introduction
Tubulin is a heterodimeric protein consisting of 50 kDa
α and β subunits. Because of its key role in cellular
division, targeting the microtubule system of eukaryotic
cells represents an attractive strategy for the develop-
ment of anticancer agents. Several research studies
have elucidated at least three distinct binding regions
on microtubules for antimitotic agents, consisting of
the taxane, vinca alkaloid, and colchicine binding sites.
Both paclitaxel, a microtubule stabilizer targeting the
taxane binding site, and vincristine, a microtubule de-
stabilizer, have been successfully used in the clinic for
the treatment of various cancers in human patients. Al-
though paclitaxel is widely used in the treatment of
breast cancer, it suffers from unexpected side effects,*Correspondence: mlb2v@virginia.edudifficulty in dosing, and lack of efficacy against multi-
drug-resistant cancer cell lines.
The development of anticancer compounds that tar-
get the colchicine binding site has been an area of ma-
jor interest. Combretastatin A-4 (CA-4), one of the most
potent antimitotic agents from the combretastatin fam-
ily, is a simple natural product isolated by Pettit and
coworkers from a bush willow tree (Combretum caf-
frum) in South Africa [1]. CA-4 exhibits potent inhibition
of tubulin polymerization through binding to the colchi-
cine binding site.
The cytotoxic effects of CA-4 against a variety of hu-
man cancer cell lines and its activity in animal xenograft
models have been reported. CA-4 was evaluated as an
experimental therapeutic in humans, but poor water
solubility unfortunately hindered its development as a
drug. However, combretastatin A-4 phophate (CA-4P),
a water-soluble disodium phosphate prodrug of CA-4,
is currently in phase I/II clinical trials, with very impres-
sive early results. Because of the clinical potential of
CA-4P, a sizeable number of CA-4 analogs have been
synthesized (Figure 1A) [2–5]. Several ligand based [6–8]
and one structure based [9] model have been estab-
lished to elucidate important SAR for the colchicine
binding site. We report here a structure-based design
for inhibitors of the colchicine binding site (Figure 1B).
Boronic acid inhibitors are of considerable interest in
drug development, and it is well known that some bo-
ronic acid compounds are potent inhibitors of serine
proteases [10]. Recently, bortezomib (VELCADE), a
modified dipeptidyl boronic acid, entered phase I/II
clinical trials [11, 12], and it has now received fast-track
approval by the Food and Drug Administration as a
treatment for multiple myeloma.
In this study, we adapted a designed methodology,
using boronic acid to mimic the OH group on the C-ring
of the CA-4 scaffold (Figure 1B), in an effort to provide
an example of the usefulness of this group as an iso-
stere for an aromatic hydroxyl group. Structure-based
modeling was used to evaluate potential interactions of
the boronic acid group with the α, β-tubulin hetero-
dimer and to help in understanding any differences in
molecular volume between CA-4 and the potential bo-
ronic acid isosteres. We also chose the boronic acid
functional group in an effort to improve the water solu-
bility of CA-4 without resorting to a prodrug strategy.
We synthesized both the cis and trans of the boronic
acid isostere of CA-4. We also obtained a single crystal
structure of each isomer to use as a starting geometry
in our modeling studies. We then investigated their in-
teraction with the colchicine binding site of tubulin by
evaluating inhibition of [3H] colchicine binding to tu-
bulin, disruption of tubulin assembly, and effects on
cancer cell growth and morphology.
Results and Discussion
The results of our modeling studies suggest that 3#-sub-
stituted boronic acids of CA-4 will mimic the 3#-OH
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1008Figure 1. Structures of Antimicrotubule Drugsphenyl of CA-4 very well. Molecular volume calcula-
tions reveal that addition of the boronic acid appeared
to add a molecular volume of 16 Å3 (approximately the
size of a water molecule) in the C-ring binding region
of the analog. As our docking model predicted, we
found that cis-6 was a potent inhibitor of the binding of
colchicine to tubulin, although it was not as strong an
inhibitor as CA-4. In contrast, cis-6 was more potent
than CA-4 in inhibiting tubulin polymerization. Concor-
dant with these biochemical findings, cis-6 disrupted
the microtubule network within the cell cytoplasm of
A-10 cells. In terms of cytotoxicity, cis-6 was somewhat
more active than CA-4 against MCF-7 human breast
cancer cells, while CA-4 was more active against the
A-10 cell line. NCI cancer cell panels showed that the
cis-boronic acid of CA-4 was also extremely potent
against a wide range of human cancer cell lines. The
effects of these agents on cell proliferation were stereo-
specific (generally, cis-6 >> trans-6), as was the case in
the biochemical assays.
The rare use of boron-containing isosteres in drug
optimization studies is puzzling. The physical proper-
ties of boronic acids appear to make this group appli-
cable to drug discovery. The pKa of boronic acid is
approximately 9–10, so it remains largely protonated
under physiological pH conditions. It has been sug-
gested that hydrogen bonds, as well as boron-nitrogen
bonds [13], can be formed, and thus boronic acid could
potentially provide a functional group that enhances
the interactions between a ligand and its protein re-
ceptor.
Solubility measurements for cis-6 and CA-4 demon-
strated that these two compounds have comparable
solubility data at pH 7.4 and distilled water. The cis-6
compound was, however, almost 2-fold more soluble
than CA-4 at pH 2. This suggest that our compound
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sis-6 will be stable and more soluble with oral delivery
see Supplemental Data for details).
Boron-containing compounds are usually air-stable
nd no special handling is needed when testing them.
oreover, there has been no reported toxicity specially
ssociated with boronic acid isosteres, and recently
ELCADE has been approved for human use in multiple
yeloma. VELCADE does undergo deboronation to form
-deboronated analogs (major metabolite), which un-
ergo hydroxylation to several inactive metabolites [14].
CA-4P (a water-soluble prodrug of CA-4) is dephos-
horylated in vivo to generate CA-4, and has a short
lasma half-life [15]. CA-4P is not active at inhibiting
ubulin polymerization or [3H] colchicine displacement.
e anticipate that hydrolysis would not occur with our
oronic acid compound, because the aryl carbon-
oron bond is not known to be subject to hydrolysis.
he expected potential increase in hydrogen bonding
f cis-6 to tubulin was an additional factor in our deci-
ion to synthesize and evaluate this compound. Finally,
he prospect of using cis-6 after tumor debulking in
onjunction with boron neutron capture therapy for
reatment of residual disease is a possibility.
hemistry
he strategy used to synthesize the cis-6 and trans-6
nalogs is outlined in Figure 2. Briefly, 3,4,5-trimethoxy-
enzaldehyde 1 was reduced by NaBH4 in methanol to
ive the alcohol 2 in 94% yield [16]. Compound 2 was
reated with phosphorus tribromide to yield the bro-
ide 3. Reaction of 3 with triphenylphosphine gave the
hosphonium salt 4 in quantitative yield. This was fol-
owed by a Wittig coupling of the phosphonium salt 4
ith 3-bromo-4-methoxybenzaldehyde in the presence
f NaHMDS/THF at −78°C, and resulted in a mixture of
tilbenes (in a 2:1 cis/trans ratio). The cis/trans mixture
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1009Figure 2. Synthesis of Boronic Acid Com-
pounds cis-6 and trans-6was purified and isomers separated by flash column
chromatography in 5% ethyl acetate/hexanes (Hex).
Conversion of the separated cis and trans isomers to
final products cis-6 and trans-6 boronic acids was ac-
complished by treating cis-5 and trans-5 independently
with trimethylboronate and n-butyllithium at −78°C.
X-Ray Crystal Structure
To obtain a good starting geometry for our structure
based approach, we obtained single crystal X-ray
structures of cis-6 and trans-6 (Figures 3A and 3B). Col-
orless needle crystals of cis-6 and trans-6 were ob-
tained by recrystallization from Hex/ethyl acetate. Mea-
surements were carried out using MoKα radiation on a
Bruker SMART APEX CCD diffractometer and an Ox-
ford Cryosystems 700 low-temperature device, and
SHELXTL software was used for the structure determi-
nation.
Molecular Modeling
Surface Volume
The surface volume contour of colchicine, cis-6, CA-4,
and water were calculated on a Silicon Graphics Oc-
tane II using SYBYL 6.8 (Tripos Inc., St. Louis, MO). The
VIEW option, CONTOUR SURFACES, was used to cre-
ate a VOLUME CONTOUR using default settings. The
contour maps in Figure 3C represent surface volumes
(at a 50.0 contour level) of the crystal structures of col-
chicine (extracted from the 1SA0), cis-6 (X-ray structure
conformation), and water (SYBYL 6.8 fragment library).
A low-energy structure of CA-4 was obtained by modi-
fying the cis-6 X-ray structure at the 3#-position within
the build/edit mode of SYBYL. Energy minimization of
the representative CA-4 was accomplished by using a
conjugate gradient approach with a 0.05 kcal energy
cutoff. Optimization was completed in less than the
1000 iterations, defined within the COMPUTE ENERGY
MODULE in SYBYL.structure was used to evaluate possible binding modes
Figure 3. Crystal Structures and Surface Volumes
(A) X-ray crystal structure of cis-6.
(B) X-ray crystal structure of trans-6.
(C) Surface volume representation of cis-6, CA-4, water, and col-
chicine.Docking
Recently, the X-ray structure of tubulin in complex with
a colchicine analog, N-deacetyl-N-(2-mercaptoacetyl)-
colchicines(DAMA-colchicine), was reported [17]. This
Chemistry & Biology
1010of cis-6 and CA-4 to the α, β-tubulin heterodimer. Using
LigandFit (Accelerys) [18], we extracted DAMA-colchi-
cine and redocked it into the originating X-ray structure
of tubulin de novo (rms = 1.1 Å between the best scored
conformer resulting from docking and the binding
mode from the X-ray structure of its complex with the
protein) as a docking calibration.
We next identified a potential binding mode of CA-4
with tubulin using the same methodology in LigandFit
and compared it to the interactions of the original
DAMA-colchicine bound within the tubulin crystal struc-
ture. LigandFit, Consensus Score [18], and visual in-
spection were used to evaluate the proposed interac-
tions. From this analysis, a top-scored conformer of
CA-4, which was selected as the most probable binding
mode, was generated.
In Figure 4, we present a representation of the results
of our docking studies. Figure 4A shows the compari-
son of the proposed binding mode of CA-4 (red) and
DAMA-colchicine (blue) originating from the X-ray
structure of the complex with tubulin. The binding site
is located between β and α subunits of tubulin, with
the ligand molecule mostly buried in the β subunit. The
binding modes of these two tubulin polymerization in-
hibitors are very similar. Both trimethoxy and phenyl
rings in the calculated binding mode of CA-4 adopt a
very similar orientation to that of the corresponding
rings (A and C) in DAMA-colchicine of the crystal struc-
ture. The alkene linkage between the two rings in CA-4
corresponds to the position of the B-ring of DAMA-col-
chicine. Moreover, the methoxy substituent of the C
ring of CA-4 is positioned in close proximity to the cor-
responding group of DAMA-colchicine. Furthermore,
the position of the hydroxyl group of CA-4 closely re-
sembles the position of the carbonyl oxygen of colchi-
cine, and the latter is involved in a hydrogen bond with
the backbone amide of Val 181 on the α subunit. Our
model shows that a similar hydrogen bond can be
formed by the hydroxyl group of CA-4. In addition, CA-4
hydroxyl group should be involved in the hydrogen
bond with the carbonyl group of Thr 179 of α-tubulin.
However, due to the geometry of this bond (distance
about 3.9 Å), this interaction might be weaker than a
normal hydrogen bond. On the other hand, colchicine
cannot be involved in this interaction, as the hydrogen
bond donor is required to be present in the ligand mole-
cule. This observation is consistent with the slightly
higher potency in the inhibition of tubulin polymeriza-
tion observed for CA-4 (IC50 = 2.2 M) as compared
with colchicine (IC50 = 3.2 M) [9].
The docking of cis-6 by LigandFit resulted in 17 clus-
ters with relatively small differences in the docking
score values between the representatives. One of these
conformers was the best scored when applying the
Consensus Score (which includes Dock_Score, PLP,
JAIN, PMF, and LUDI scoring functions [see Supple-
mental Data for details) [18]. Therefore, based both on
the visual inspection and on the Consensus Scoring re-
sults, a single representative conformer was selected
as the most probable binding mode of cis-6 to tubulin
(Figure 4B). In general, the calculated binding mode of
cis-6 is similar to the one described above for CA-4.
However, due to the replacement of the hydroxyl group
of CA-4 by a larger boronic group in cis-6, the position
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sigure 4. Binding Models of Colchicine, CA-4, and cis-6
A) Proposed binding mode of CA-4 to tubulin. Protein originates
rom the X-ray structure of its complex with DAMA-colchicine (en-
oded as 1SA0 in PDB). DAMA-colchicine is presented in blue,
A-4 in red. β-Tubulin is shown in a ribbon representation in
A)–(C), and the residues of α-tubulin involved in the interactions
ith CA-4 are shown as capped sticks.
B) Comparison of the proposed binding modes of CA-4 (red) and
is-6 (yellow) to tubulin with DAMA-colchicine binding mode (blue)
riginating from the X-ray structure of its complex with tubulin
1SA0).
C) Comparison of the proposed binding modes of cis-6 (yellow)
nd CA-4 (red) to tubulin.f the latter ligand is slightly shifted in the tubulin bind-
ng site toward the β subunit to accommodate the
lightly larger boronic group (Figure 4B). Molecular vol-
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1011ume studies (Figure 3C) reveal that the addition of a
−B(OH)2 adds approximately the molecular volume of
H2O (16 Å3). This would make the total molecular vol-
ume of cis-6 slightly larger than that of colchicine (266.7
versus 271.5 Å3).
Our docking studies also suggest that one of the hy-
droxyl groups of the boronic acid is placed in a very
similar position to the hydroxyl group of CA-4, and it
establishes a hydrogen bond with the backbone amide
of Val 181 of α-tubulin. The second hydroxyl of boronic
acid in cis-6 forms a hydrogen bond with the backbone
carbonyl of Thr 179 of α-tubulin. The geometry for this
interaction is better than that for CA-4, as the hydroxyl
of the boronate in cis-6 can approach closer to Thr 179
(Figure 4C). This is consistent with the slightly higher
potency of cis-6 for the inhibition of tubulin polymeriza-
tion (IC50 = 1.5 M) and the growth of MCF-7 human
breast carcinoma cells (IC50 = 17 nM) as compared with
CA-4.
Biological Data
The boronic acid analogs cis-6 and trans-6 were eval-
uated for their ability to bind to the colchicine site by
inhibition of the binding of [3H] colchicine. The cis-
boronic acid 6 was slightly less inhibitory than CA-4
when evaluated at 5 and 50 M (Table 1). However,
cis-6 was slightly more active as an inhibitor of tubulin
polymerization (Table 1) compared with CA-4. These re-
sults demonstrate quite clearly that the cis-boronic
acid 6 is a viable bioisostere of CA-4.
Comparison of activities of cis-6 and trans-6 as inhib-
itors of tubulin polymerization, colchicine binding, and
MCF-7 cell proliferation all confirm the high selective
preference for the cis conformation over the trans.
These results agree with extensive literature data dem-
onstrating the increased activity of numerous cis as
compared with trans analogs of CA-4 [19].
To evaluate the effects of our isostere cis-6 on intra-
cellular microtubules, indirect immunofluorescence was
used to visualize the effects of these analogs on micro-
tubules of A-10 cells. In the control (Figure 5A), the
microtubule network and nuclei are clearly visible.
When the cells were treated with CA-4 (Figure 5B), the
network of microtubules was completely lost, but the
nuclei were still visible. However, in the cells treated
with cis-6 (Figure 5C), a complete loss of the microtu-
bule network occurred, and the cell nuclei were less
distinct. The corresponding EC value for each com-Table 1. Inhibition of Tubulin Polymerization, Growth of MCF-7 Human Breast Carcinoma Cells, the Binding of [3H] Colchicine to Tubulin,
and EC50 for Loss of Microtubules in A-10 Cells
[3H] Colchicine Bindingc (% ± SD)Tubulina MCF-7b
Compound IC50 ± SD (M) IC50 ± SD (nM) 5 M 50 M A-10 EC50 (M)d
cis-6 1.5 ± 0.2 17 ± 5 79 ± 1.7 99 ± 2.1 0.058
trans-6 7.8 ± 1.4 470 ± 140 13 ± 6.5 51 ± 8.1 >15
CA-4 2.0 ± 0.1 32 ± 21 99 ± 2.0 N/D <0.025
N/D, no data.
a Inhibition of tubulin polymerization. Tubulin was at 10 M.
b Inhibition of growth of MCF-7 human breast carcinoma cells.
c Inhibition of colchicine binding. Compounds cis-6 and trans-6 were tested at 5 and 50 M. The tubulin concentration was 1 M, and [3H]
colchicine concentration was 5 M. All experiments were performed in triplicate with reported standard deviation (SD).
d The percentage of cellular microtubule loss was estimated visually over a range of concentrations. Dose-response curves were generated
and EC50 values calculated. The values represent the results of two independent experiments.50pound is shown in Table 1. For cis-6, an EC50 of 0.058
M was found as a concentration at which 50% of the
intracellular microtubule network of A-10 cells was dis-
rupted. These data provide additional evidence, be-
sides the cytotoxic results presented above and below,
that boronic acid isosteres of CA-4 can easily penetrate
the cell membrane in the low- to mid-nanomolar range.
The antiproliferative profile of the boronic acid CA-4
mimetics, cis-6 and trans-6, were evaluated at the Na-
tional Cancer Institute (NCI) against 53 human cancer
cell lines. The results are shown in Table 2. Compound
cis-6 was extremely active toward 43 out of 53 human
cancers, with GI50 values below 10 nM. The trans-6 iso-
mer was found to be significantly less active in every
line examined except the U251 central nervous system
cancer cell line. This is consistent with all of our pre-
viously presented results.
Significance
In this study, we designed boronic acid mimetics of
the phenol of CA-4. The addition of boronic acid adds
approximately the surface volume of the water mole-
cule. Docking studies suggested that the combreta-
statin boronic acid cis-6 would bind to the colchicine
binding site on -tubulin as well as to amino acids on
-tubulin. We confirmed that the cis-6 analog was
able to inhibit [3H] colchicine binding to -tubulin with
a 79% inhibition at 5 M (in 1:1 ratio with [3H] colchi-
cine). Compound cis-6 also inhibited tubulin polymer-
ization with an IC50 of 1.5 ± 0.2 M. Indirect immuno-
fluorescence studies revealed that the cis-6 analog
could penetrate the cell membrane and inhibit intra-
cellular microtubules of A-10 cells with an EC50 value
of 0.058 M. Treatment of 53 human cancer cell lines
with the cis-6 compound resulted in the growth inhibi-
tion of 43 cell lines at GI50 values below 10 nM. Alto-
gether, our results demonstrate that arylboronic acids
provide a viable biomimetic of phenol groups, and
this isostere represents a new class of potent analogs
of CA-4.
Experimental Procedures
Chemistry: General Methods
NMR spectra were recorded using a Varian-300 spectrometer for
1H (300 MHz) and 13C (75 MHz). Chemical shifts (δ) are given in ppm
downfield from tetramethylsilane as internal standard, and coupling
Chemistry & Biology
1012Figure 5. Effects of CA-4 and cis-6 on Interphase Microtubules in A-10 Cells
(A) Vehicle control.
(B) 50 nM CA-4.
(C) 100 nM Compound cis-6.constants (J values) are in hertz. Mass spectra data were collected
on a Finnigan MAT LC-Q mass spectrometer system using electro-
spray ionization (ESI). Elemental analyses were performed by Atlan-
tic Microlabs. Melting points were obtained using an electrothermal
digital melting point apparatus and are uncorrected. All purifica-
tions by flash chromatography were performed using Geduran sil-
ica gel 60, 35–75 m (VWR Scientific, West Chester, PA). All
solvents used were purified by pressure filtration through activated
alumina. Reactions were run at ambient temperature and under a
nitrogen atmosphere, unless otherwise noted, and were monitored
by TLC using Merck 60 F254 silica gel aluminium sheets (20 × 20 cm).
(3,4,5-Trimethoxyphenyl)methanol (2)
Sodium borohydride (1.06 g, 28.0 mmol) was added to a solution
of 3,4,5-trimethoxybenzaldehyde (5.0 g, 25.5 mmol) in absolute
methanol (50 ml) and stirred for 30 min. After completion of the
reaction, water (15 ml) was added, and the solution was extracted
with ethyl acetate (EtOAc) (3 × 30 ml). The combined extracts were
washed with brine (30 ml) and dried over sodium sulfate. Rotary
evaporation afforded alcohol 2 as a clear oil (4.73 g, 94%): 1H NMR
(CDCl3, 300 MHz) δ 6.47 (s, 2H), 4.48 (s, 2H), 3.72 (s, 9H), 3.24 (s, 1H).
5-(Bromomethyl)-1,2,3-trimethoxybenzene (3)
The alcohol 2 (4.7 g, 23.7 mmol) was dissolved in dry CH2Cl2 (40
ml) and cooled to 0°C. Phosphorus tribromide (2.25 ml, 23.7 mmol)
was added dropwise, and the reaction mixture was warmed to
room temperature and stirred overnight; 5% NaHCO3 was added,
and the CH2Cl2 layer was separated and dried over sodium sulfate.
The CH2Cl2 layer was filtered, and concentrated by rotary evapora-
tion, and the residue was purified by flash column over silica using
5% EtOAc/Hex to give a white solid 3 (3.7 g, 60%): 1H NMR (CDCl3,
300 MHz) δ 6.62 (s, 2H), 4.47 (s, 2H), 3.87 (s, 6H), 3.85 (s, 3H).
3,4,5-Trimethoxybenzyltriphenylphosphonium bromide (4)
Triphenylphosphine (4.1 g, 15.6 mmol) was added to a solution of
3 (3.1 g, 12.0 mmol) in dry THF (30 ml). The mixture was refluxed
with stirring for 6 hr. The resulting white solid was filtered and
washed with ether/Hex to afford the product 4 in quantitative yield:
1H NMR (CDCl3, 300 MHz) δ 7.78 (s, 15H), 6.23 (s, 2H), 5.05 (d, 2H,
J = 15 Hz), 3.59 (s, 3H). 3.36 (d, 6H, J = 15 Hz).
5-[(Z)-2-(3-Bromo-4-methoxyphenyl)vinyl]-1,2-3-
trimethoxybenzene (cis-5)
Phosphonium bromide 4 (1.22 g, 2.33 mmol) was suspended in dry
THF and cooled to −78°C. Sodium bis(trimethylsilyl)amide (2.56 ml,
2.56 mmol, 1.0 M in THF) was added slowly with stirring. The mix-
ture was stirred at −78°C for 3 hr, and 3-bromo-4-methoxybenzal-
dehyde (0.56 g, 2.56 mmol) in 5 ml THF was added dropwise. The
reaction temperature was maintained at −78°C for another hour,
and the mixture was warmed to room temperature. The reaction
mixture was stirred for 4.5 hr until the red solution became pale
yellow. The yellow solution was poured into saturated NH4Cl (20 ml)
and extracted with EtOAc. The extracts were combined, washed
with brine, and dried over Na2SO4. The organic layer was filtered
and rotary concentrated to give the crude mixture of cis/trans stil-
bene 5. Flash column chromatography using 5% EtOAc/Hex eluted
the cis-stilbene 5 (Rf = 0.41, Hex/EtOAc = 3/1) as a white solid
(354.3 mg, 40%): mp 100°C–102°C. 1H NMR (CDCl , 300 MHz) δ
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α3.56 (s, 1H), 7.20 (d, 1H, J = 8.4 Hz), 6.73 (d, 1H, J = 8.7 Hz), 6.51
s, 2H). 6.46 (d, 1H, J = 12.3 Hz), 6.41 (d, 1H, J = 12.3 Hz), 3.88 (s,
H), 3.85 (s, 3H), 3.71 (s, 6H); 13C NMR (75.5 MHz) δ 154.8, 152.9,
37.3, 133.6, 132.2, 131.0, 129.8, 129.3, 127.8, 111.4, 111.0, 105.9,
0.8, 56.1, 55.9; ESI m/z 380 (M + H)+.
-[(E)-2-(3-Bromo-4-methoxyphenyl)vinyl]-1,2-3-
rimethoxybenzene (trans-5)
lash column as described above yielded stilbene trans-5 (Rf =
.31, Hex/EtOAc = 3/1) as a pale yellow solid (180.0 mg, 20%): mp
50°C–152°C. 1H NMR (CDCl3, 300 MHz) δ 7.75 (d, 1H, J = 2.1), 7.40
dd, 1H, J = 2.1, 2.1 Hz), 6.91 (s, 2H), 6.89 (s, 1H). 6.72 (s, 2H), 3.92
s, 9H), 3.85 (s, 3H); 13C NMR (75.5 MHz) δ 155.3, 153.4, 137.8,
32.9, 131.5, 130.8, 127.8, 126.8, 126.2, 112.0, 111.9, 103.4, 61.0,
6.3, 56.1; ESI m/z 380 (M + H)+.
-Methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]boronic
cid (cis-6)
is-5 (1.35 g, 3.56 mmol) was dissolved in dry THF (50 ml) and
ooled to −78°C, and n-BuLi (3.34 ml, 5.34 mmol, 1.6 M in Hex)
as added dropwise. The resulting mixture was stirred at −78°C
or another 1.5 hr, followed by the dropwise addition of trimethyl
orate (0.55 g, 5.34 mmol) dissolved in 5 ml THF. The mixture was
armed to room temperature and stirred overnight. The reaction
as quenched with 3 N HCl (10 ml) and stirred at room temperature
or 30 min, followed by washing with ether (3 × 30 ml). The com-
ined ether layers were extracted with 1 N NaOH (2 × 20 ml), and
he basic layers were reacidified with 1 N HCl to pH 4. After reacidi-
ication, the mixture was extracted with ether (2 × 30 ml), and the
ther layers were combined. The combined ether layers were dried
ver Na2SO4, filtered, and concentrated to afford a pale yellow oil.
lash column chromatography using 20% EtOAc/Hex eluted the
is- 6 (Rf = 0.4, Hex/EtOAc = 1/2) as a sticky oil (1.10 g, 90%).
ecrystallization of the oil in Hex/EtOAc resulted in white crystal-
ine needles of cis-6: mp 109°C–110°C. 1H NMR (CDCl3, 300 MHz)
7.83 (d, 1H, J = 2.4), 7.34 (dd, 1H, J = 2.4, 2.4 Hz), 6.78 (d, 1H, J =
.7 Hz), 6.52 (m, 4H). 5.81 (broad, 2H), 3.90 (s, 3H), 3.85 (s, 3H), 3.70
s, 6H); 13C NMR (75.5 MHz) δ 163.82, 153.13, 137.94, 137.29,
33.64, 132.99, 130.33, 129.60, 129.42, 129.34, 109.87, 106.09,
1.13, 56.11, 55.84; ESI m/z 345 (M + H)+. Analysis calculated for
18H21BO6: C, 62.82; H, 6.15. Found: C, 62.80, H, 6.21.
-Methoxy-5-[(E)-2-(3,4,5-trimethoxyphenyl)vinyl]boronic
cid (trans-6)
ompound trans-6 was obtained in 82% yield from the trans-5 fol-
owing the same procedure as described above; mp 120°C–122°C.
H NMR (CDCl3, 300 MHz) δ 8.03 (d, 1H, J = 2.4), 7.59 (dd, 1H, J =
.7, 2.4 Hz), 7.00 (s, 2H), 6.94 (d, 1H, J = 8.7 Hz), 6.74 (s, 2H), 5.92
broad, 2H), 3.96 (s, 3H), 3.92 (s, 6H), 3.88 (s, 3H); 13C NMR (75.5
Hz) δ 164.32, 153.61, 136.06, 135.12, 133.52, 131.03, 130.62,
28.18, 127.57, 127.39, 110.55, 103.55, 61.18, 56.31, 55.93; ESI
/z 345 (M + H)+. Analysis calculated for C18H21BO6: C, 62.82; H,
.15. Found: C, 62.74, H, 5.97.
olecular Modeling
ocking
he X-ray structure of tubulin originating from the complex of two
, β-heterodimers with DAMA-colchicine, and the stathmin-like do-
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1013Table 2. National Cancer Institute Cancer Cell Line GI50 Values
GI50 (M)
Cell Line cis-6 trans-6
Leukemia
CCRF-CEM <0.01 10.2
K-562 <0.01 4.1
MOLT-4 <0.01 13.8
RPMI-8226 <0.01 5.9
SR <0.01 2.3
Non-small cell lung cancer
A549/ATCC <0.01 3.7
EKVX <0.01 3.4
HOP-62 <0.01 5.6
HOP-92 <0.01 2.4
NCI-H226 9.92 12.5
NCI-H23 <0.01 3.3
NCI-H322M <0.01 8.1
NCI-H460 <0.01 3.2
NCI-H522 <0.01 3.6
Colon cancer
COLO 205 2.77 21.5
HCC-2998 <0.01 4.6
HCT-116 <0.01 4.2
HCT-15 4.62 27.3
KM12 <0.01 3.8
SW-620 <0.01 4.3
CNS cancer
SF-268 0.029 12.0
SF-295 <0.01 3.5
SF-539 <0.01 3.3
SNB-19 <0.01 16.1
U251 5.17 2.5
Melanoma
LOX IMVI 5.38 21.8
MALME-3M 0.039 13.0
M14 <0.01 3.9
SK-MEL-2 <0.01 12.1
SK-MEL-5 <0.01 2.7
UACC-257 ND 8.1
UACC-62 <0.01 2.9
Ovarian cancer
IGROV1 <0.01 5.8
OVCAR-3 <0.01 16.7
OVCAR-4 15.80 22.9
OVCAR-5 <0.01 3.2
OVCAR-8 <0.01 3.6
SK-OV-3 5.38 9.4
Renal cancer
786-0 <0.01 4.7
A498 <0.01 2.9
ACHN 9.27 32.0
CAKI-1 <0.01 18.2
RXF 393 <0.01 2.4
SN12C <0.01 8.0
TK-10 <0.01 21.4
UO-31 <0.01 4.7
Prostate cancer
PC-3 <0.01 2.4
DU-145 <0.01 2.6
Breast cancer
MCF7 <0.01 3.2
NCI/ADR-RES <0.01 2.3
MDA-MB-231/ATCC <0.01 3.5
HS 578T <0.01 2.5
MDA-MB-435 <0.01 3.1
BT-549 <0.01 3.3main (SLD) of RB3 (encoded as 1SA0 in PDB) was applied for all
docking experiments. The colchicine binding site, located between
α- and β-tubulin, was used to perform docking of CA-4 and com-pounds cis-6 and trans-6. The hydrogen atoms were added to the
protein using the Insight II/Builder (Accelrys, San Diego, CA) pro-
gram [20]. The protonation states of tubulin residues were selected
for pH = 7.0. LigandFit [18] from Cerius2 4.8.1 version [21], within
the Accelrys suite of programs, was applied for all docking studies
using the Dreiding force field [22]. The site for docking of ligands
was defined based on the position of DAMA-colchicine in the tu-
bulin crystal structure. The X-ray structure of cis-6 and the model
of CA-4, resulting from the replacement of the boronic group in
cis-6 by a hydroxyl group, were used as starting conformations
for docking experiments. Flexible docking, employing Monte Carlo
simulations (100,000 trials), was performed with LigandFit, using
soft potential for interaction energy calculations [18]. The 100 low-
est energy and diverse docking conformations were saved and
clustered, using the Leader method with the rms distance thresh-
old of 1.5 Å. The best member from each cluster was saved for
further analysis. Moreover, several scoring functions, Dock_Score,
PLP, JAIN, PMF, and LUDI, as implemented in Cerius2 [21], were
also applied to prioritize the docking conformation output with
each ligand. Subsequently, a consensus score was calculated for
each docked ligand in each conformation. Based on the scoring
results and on the visual inspection of the proposed interaction
modes, the best fit for each ligand was selected. The protein-ligand
complexes were then placed in a 5 Å thick layer of water molecules
and subjected to further refinement, using the Discover/InsightII
program [23]. Optimization of protein-ligand models was performed
using the CVFF force field, adding corresponding partial charges
to all atoms. The polypeptide backbone atoms of tubulin remained
frozen, while the protein side chains, ligand and water molecules
were free during the optimization procedure. The conjugate gradi-
ent algorithm was applied for minimization, which was continued
until the rms derivative was lower than 0.02 kcal/mol·Å. A twin cut-
off (18.0 Å, 20.0 Å) was used to calculate the nonbonded interac-
tions at each minimization step.
Biological Testing
[3H] Colchicine Binding Assays
The binding of [3H] colchicine to tubulin was measured by the
DEAE-cellulose filter method, as described in detail previously [24].
The tubulin concentration was 1.0 M (0.1 mg/ml), and the [3H]
colchicine concentration was 5.0 M.
MCF-7 Cell Proliferation Assay
IC50 values for inhibition of cell growth were obtained by measuring
the amount of total cell protein with the sulforhodamine B (SRB)
assay [25]. The MCF7 cells were grown for 24 hr with and without
drug. IC50 values were determined after an additional 48 hr.
Tubulin Polymerization
Tubulin polymerization was followed turbidimetrically at 350 nm
in Beckman model DU-7400 and Du7500 spectrophotometers
equipped with electronic temperature controllers, as described in
detail previously [26]. The tubulin concentration was 10 M (1.0 mg/ml).
Indirect Immunofluorescence
Drug effects on the microtubule network of A-10 cells were eval-
uated by indirect immunofluorescent techniques as previously de-
scribed [27]. Cells were plated onto glass coverslips and treated
with a range of compounds for 18 hr. The cells were fixed and
microtubules visualized using a β-tubulin antibody, and nuclei were
stained with 4,6-diamidino-2-phenylindole. Cells were examined
with a Nikon ES800 fluorescence microscope, and images were
captured with a Photometrics Cool Snap FX3 camera and compiled
using Metamorph software.
NCI Human Cancer Cell Proliferation Assay
Compounds were tested against 53 human tumor cell lines at 5
concentrations in a 10-fold serial dilution. After a 48-hr incubation,
an SRB protein assay was used to determine inhibition of cell
growth. GI50 values were calculated from log dose-response curves
(see [28] for additional details concerning this screen and the NCI’s
drug discovery and development program).
Solubility Testing
Solubility of cis-6 and CA-4 were analyzed on a Shimadzu 10 AD-
VP system using a Waters’ Atlantis dC18 (5 m 4.6 × 150 mm) col-
umn with a linear gradient from 30%–60% MeOH/Water (containing
0.1% formic acid) over 15 min. A total of 3.0 mg of each cis-6 and
Chemistry & Biology
1014CA-4 were suspended in the three solutions and agitated at 37°C
for 24 hr. The supernatant was then removed and filtered through
a 0.45 m PTFE acrodisc filter. The concentration of the samples
was analyzed using HPLC and quantified using a known standard
of 100 g/ml.
Supplemental Data
Supplemental Data, including crystal structure data for cis-6 and
trans-6, docking score values for different conformers of cis-6 and
CA-4, solubility data for cis-6 and CA-4, and a more detailed analy-
sis of the binding mode of CA-4 and its derivatives are available at
http://www.chembiol.com/cgi/content/full/12/9/1007/DC1/.
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